1. Search Result
Search Result
Results for "

H3B

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Fluorescent Dye

1

Peptides

3

Inhibitory Antibodies

12

Recombinant Proteins

17

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111517

    Apoptosis SF3B1 Cancer
    H3B-8800 is a potent and orally active SF3B splicing modulator. H3B-8800 direct interaction with the SF3b complex and shows anti-cancer activity. H3B-8800 has the potential for the research of acute myeloid leukemia (AML) with SF3B1 mutant .
    H3B-8800
  • HY-P3371

    DS-7300a; MABX-9001a; I-DXd

    Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis Cancer
    Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects [3]
    Ifinatamab deruxtecan
  • HY-136128
    H3B-120
    1 Publications Verification

    Potassium Channel Carbamoyl Phosphate Synthetase (CPS) Cancer
    H3B-120 is a highly selective, competitive and allosteric carbamoyl phosphate synthetase 1 (CPS1) inhibitor with an IC50 of 1.5 μM and a Ki of 1.4 μM. H3B-120 has anti-cancer activity .
    H3B-120
  • HY-P99762
    Obrindatamab
    1 Publications Verification

    MGD009

    CD3 Cancer
    Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
    Obrindatamab
  • HY-100491

    FGFR Cancer
    H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity .
    H3B-6527
  • HY-112611

    Estrogen Receptor/ERR Cancer
    H3B-5942 is a selective, irreversible and orally active estrogen receptor covalent antagonist, inactivates both wild-type and mutant ERα by targeting Cys530, with Kis of 1 nM and 0.41 nM, respectively. H3B-5942 reduces ERα target gene GREB1, shows potent antitumor activity both in multiple cell lines or animals bearing ERα WT or ERα mutations .
    H3B-5942
  • HY-112596
    H3B-6545
    3 Publications Verification

    Estrogen Receptor/ERR Cancer
    H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer .
    H3B-6545
  • HY-112596A
    H3B-6545 hydrochloride
    3 Publications Verification

    Estrogen Receptor/ERR Cancer
    H3B-6545 hydrochloride is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer .
    H3B-6545 hydrochloride
  • HY-149887
    H3B-968
    1 Publications Verification

    DNA/RNA Synthesis Cancer
    H3B-968 is the ATP-competitive inhibitor of Werner syndrome protein (WRN) with an IC50 of about 10 nM .
    H3B-968
  • HY-145636

    AEX4089DC1; MGC018

    Antibody-Drug Conjugates (ADCs) Cancer
    Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity .
    Vobramitamab duocarmazine
  • HY-100491R

    FGFR Reference Standards Cancer
    H3B-6527 (Standard) is the analytical standard of H3B-6527 (HY-100491). This product is intended for research and analytical applications. H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity .
    H3B-6527 (Standard)
  • HY-183888

    Carbamoyl Phosphate Synthetase (CPS) Cancer
    H3B-616 is a selective carbamoyl phosphate synthetase 1 (CPS1) inhibitor with a human IC50 of 66 nM. H3B-616 binds to an allosteric pocket in the CPS1 integrating domain to exert target engagement and inhibit enzyme activity. H3B-616 can be used for the research of nonsmall cell lung cancer and gastric cancer .
    H3B-616
  • HY-P10687

    RXFP Receptor Others
    H3B10-27(13/17αF) is an excellent scaffold for further developing reagent candidates and an important tool for understanding the physiological functions of the neuropeptide G protein-coupled receptor RXFP3, and it's very stable in serum .
    H3B10-27(13/17αF)
  • HY-185279

    HS-20093; GSK5764227

    Antibody-Drug Conjugates (ADCs) CD276/B7-H3 Cancer
    Risvutatug rezetecan (HS-20093; GSK5764227) is a B7-H3-targeting antibody-drug conjugate (ADC). Risvutatug rezetecan binds to B7-H3 on tumor cells and delivers a topoisomerase I inhibitor payload via a tumor microenvironment-responsive cleavable linker. Risvutatug rezetecan is applicable for the research of extensive-stage small cell lung cancer and non-small cell lung cancer .
    Risvutatug rezetecan
  • HY-P992347

    CD276/B7-H3 Cancer
    DS-5573a is a human monoclonal antibody targeting B7-H3, with a Kd of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer .
    DS-5573a

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: